rs662799 — APOA5 -1131T>C

APOA5 — The Triglyceride Traffic Controller

Apolipoprotein A5 (APOA5) is a liver-secreted protein that acts as a critical regulator of circulating triglyceride levels. Though present in plasma at very low concentrations, APOA5 has an outsized effect on fat clearance¹¹ APOA5 has an outsized effect on fat clearance
Plasma APOA5 concentrations are 1,000-fold lower than APOA1 yet exert comparable effects on triglyceride metabolism by facilitating the activity of lipoprotein lipase (LPL)²² lipoprotein lipase (LPL)
The enzyme anchored to capillary walls that breaks down triglycerides in VLDL and chylomicrons, the enzyme responsible for breaking down fat-carrying particles in the bloodstream. The -1131T>C promoter variant (rs662799) reduces how much APOA5 the liver produces, weakening this clearance system and allowing triglycerides to accumulate in circulation.

The Mechanism

The -1131T>C change sits in the promoter region of the APOA5 gene, approximately 1,131 base pairs upstream of where gene transcription begins. The C allele (reported as the G allele on the forward genomic strand by 23andMe) impairs ribosomal translation efficiency³³ impairs ribosomal translation efficiency
In vitro studies show reduced translational efficiency of mRNA carrying the -1131C allele, resulting in lower circulating APOA5 protein levels. With less APOA5 available, LPL activity at the capillary surface is reduced⁴⁴ LPL activity at the capillary surface is reduced
APOA5 tethers LPL to heparan sulfate proteoglycans on capillary endothelium and stabilizes the enzyme, slowing the breakdown of triglyceride-rich lipoproteins (VLDL and chylomicrons). The result is slower postprandial triglyceride clearance and higher fasting triglyceride levels.

The effect is additive — each copy of the C (A on forward strand) risk allele progressively reduces APOA5 expression and raises triglycerides. The variant is part of the APOA5*2 haplotype⁵⁵ APOA5*2 haplotype
A group of co-inherited APOA5 promoter variants including rs662799, rs651821, rs2072560, and rs2266788 associated with hypertriglyceridemia susceptibility.

The Evidence

The rs662799 -1131C allele is one of the most replicated genetic determinants of circulating triglycerides in the human genome. A meta-analysis of 51,868 participants⁶⁶ meta-analysis of 51,868 participants
Including 46 East Asian studies, 26 European studies, and 19 studies of other ethnic groups confirmed the C allele raises fasting triglycerides by a weighted mean difference of 0.30 mmol/L (about 26 mg/dL) and increases metabolic syndrome risk with an OR of 1.33 (95% CI 1.16–1.53) in the overall population. In a Hong Kong and Guangzhou Chinese cohort, plasma triglycerides were 36.1% higher in CC versus TT homozygotes⁷⁷ plasma triglycerides were 36.1% higher in CC versus TT homozygotes
OR for hypertriglyceridemia ≥1.7 mmol/L was 2.22 (1.44–3.43) for CC and 1.81 (1.37–2.39) for TC.

The cardiovascular consequences are also significant. A meta-analysis of 49,806 individuals⁸⁸ meta-analysis of 49,806 individuals
21,378 CHD cases and 28,428 controls across 10 ethnic populations showed the C allele significantly increases coronary heart disease risk (OR ~1.27 at the allele level, P < 0.00001), with consistent effects across Chinese, other Asian, and Caucasian populations.

Practical Actions

The dietary implications of this variant are particularly clear. C allele carriers appear to have a blunted metabolic response to caloric restriction and dietary fat improvement⁹⁹ C allele carriers appear to have a blunted metabolic response to caloric restriction and dietary fat improvement
Caucasian obese subjects: TG reduction −19.3 vs −4.2 mg/dL in TT vs C carriers after Mediterranean diet intervention. In a study of 363 obese Caucasian subjects, TT homozygotes achieved significant reductions in triglycerides, insulin, and insulin resistance (HOMA-IR) on a hypocaloric Mediterranean-pattern diet, while C allele carriers showed no statistically significant improvement on any of these metabolic parameters.

The fat quality appears to matter more than quantity for C allele carriers. Specifically, high n-6 polyunsaturated fat intake exacerbates the adverse effect¹⁰¹⁰ high n-6 polyunsaturated fat intake exacerbates the adverse effect
Dietary n-6 PUFA intake modulates the APOA5 effect on plasma TG and remnant lipoprotein concentrations of the risk allele on triglycerides, suggesting that correcting an omega-6:omega-3 imbalance is especially important. Increasing EPA and DHA intake through fatty fish or high-dose fish oil supplements is the most evidence-based strategy for reducing triglycerides in C allele carriers whose lifestyle interventions have had limited effect.

Monitoring fasting triglycerides regularly allows early detection of deterioration before cardiovascular risk accumulates. A fasting TG above 1.7 mmol/L (150 mg/dL) is the threshold for the metabolic syndrome criterion and a reasonable alert level for C allele carriers to intensify dietary and supplementation efforts.

Interactions

The rs662799 variant is part of the APOA5*2 haplotype, which co-segregates with other APOA5 variants — notably rs651821 (-3A>G), rs2072560 (715G>T), and rs2266788 (1891T>C). These variants are in partial linkage disequilibrium and collectively define haplotype-level triglyceride risk. Having multiple APOA5 risk alleles compounds the effect.

APOA5 interacts with the APOE genotype in determining triglyceride clearance and cardiovascular risk. APOE4 carriers (rs429358) with a concurrent APOA5 risk allele may have amplified dyslipidemia because both proteins affect VLDL metabolism through overlapping but distinct pathways — APOE governs VLDL receptor binding while APOA5 controls LPL activity. Individuals with both variants may benefit most from aggressive triglyceride management.

The rs3135506 variant (APOA5*3, Ser19Trp) is separately and independently associated with hypertriglyceridemia through a different mechanism (reduced LPL binding affinity). Carrying both rs662799 and rs3135506 risk alleles represents a compounded impairment in triglyceride clearance capacity.